Schistosomiasis Mansoni
10
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
30%
3 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Praziquantel in Children Under Age 4
Single-sex Female Controlled Human Schistosomiasis Mansoni Infection
Evaluation of an AI-DP for STH Deworming Programs: a Study Protocol
Female Genital Schistosomiasis in Tanzania
Anti-Schistosomiasis Sm14-vaccine in Senegal
Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil
Safety and Efficacy of Mirazid for Schistosomiasis Treatment
Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery
Evaluation of the Use of a Urin Test Strip to Determine the Spread of Schistosoma Infections in Areas Where Schistosomiasis Infections Are Low in Kenya